Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $24.35, but opened at $26.02. TG Therapeutics shares last traded at $24.82, with a volume of 814,518 shares changing hands.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on TGTX shares. TD Cowen started coverage on TG Therapeutics in a report on Tuesday. They issued a "buy" rating and a $50.00 target price for the company. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $49.00 target price on shares of TG Therapeutics in a report on Wednesday, September 18th. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.43.
Check Out Our Latest Report on TG Therapeutics
TG Therapeutics Trading Up 5.6 %
The firm has a market capitalization of $3.97 billion, a P/E ratio of 111.17 and a beta of 2.21. The firm has a fifty day simple moving average of $23.42 and a two-hundred day simple moving average of $19.77. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business's quarterly revenue was up 357.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.34) earnings per share. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On TG Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 485 shares in the last quarter. Quarry LP raised its position in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 503 shares in the last quarter. Private Advisor Group LLC raised its position in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 542 shares in the last quarter. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 849 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock valued at $538,000 after acquiring an additional 1,322 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
TG Therapeutics Company Profile
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
